Mechlorethamine
- Generic Name
- Mechlorethamine
- Brand Names
- Valchlor, Ledaga
- Drug Type
- Small Molecule
- Chemical Formula
- C5H11Cl2N
- CAS Number
- 51-75-2
- Unique Ingredient Identifier
- 50D9XSG0VR
- Background
A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage.
The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl.
- Indication
For the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. Also for the palliative treatment of metastatic carcinoma resulting in effusion.
- Associated Conditions
- Bronchogenic Carcinoma, Chronic Lymphocytic Leukemia, Hodgkins Disease (HD), Lymphoma, Diffuse, Mycosis Fungoides (MF), Polycythemia Vera (PV), Stage I Mycosis Fungoides, Malignant effusion
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
- Conditions
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 10
- Registration Number
- NCT06149247
- Locations
- 🇺🇸
Rochester Skin Lymphoma Medical Group, Fairport, New York, United States
Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Centre for Human Drug Research, Netherlands
- Target Recruit Count
- 32
- Registration Number
- NCT05303480
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.
- Conditions
- Cutaneous T-cell LymphomaMycosis Fungoides of Skin (Diagnosis)Non Hodgkin LymphomaLymphomatoid PapulosisLymphoma, Large-Cell, AnaplasticLymphoma, Follicular
- Interventions
- Device: Med-Jet InjectorDevice: Conventional syringe
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT05106192
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)
- Conditions
- Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (Stage IA-IB)
- Interventions
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2023-11-09
- Target Recruit Count
- 2
- Registration Number
- NCT04218825
- Locations
- 🇫🇷
CHU de Bordeaux - Groupe Hospitalier Saint-Andre - Hopital Saint-Andre, Bordeaux, France
🇫🇷Assistance Publique Hopitaux Paris- APHP - APHP Nord - Univ De Paris Cite - Hop. Saint Louis, Paris, France
Valchlor in the Treatment of Lichen Planopilaris
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT03417141
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Mechlorethamine Induced Contact Dermatitis Avoidance Study
- Conditions
- Cutaneous T-cell LymphomaMycosis FungoidesFolliculotropic Mycosis FungoidesMycosis Fungoides VariantTransformed Mycosis FungoidesCutaneous T-cell Lymphoma Stage IGranulomatous Slack SkinSyringotropic Mycosis Fungoides
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Rochester Skin Lymphoma Medical Group, PLLC
- Target Recruit Count
- 28
- Registration Number
- NCT03380026
- Locations
- 🇺🇸
Rochester Skin Lymphoma Medical Group, PLLC, Fairport, New York, United States
Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides
- Conditions
- Mycosis Fungoides
- Interventions
- Procedure: Total Skin Electron Beam Radiation Therapy
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Effect of Vitamin D After Application With Valchlor
- Conditions
- Skin Irritation
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT02968446
- Locations
- 🇺🇸
University Hospitals, Cleveland, Ohio, United States
Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides
- Conditions
- Cutaneous T-cell LymphomaMycosis Fungoides
- Interventions
- Radiation: Total skin electron beam therapy (TSEBT)
- First Posted Date
- 2016-08-29
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 68
- Registration Number
- NCT02881749
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Helsinn Therapeutics (U.S.), Inc
- Target Recruit Count
- 300
- Registration Number
- NCT02296164
- Locations
- 🇺🇸
Investigator Site, Fairfax, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.